The Role of Lipoprotein (a) as a Marker of Residual Risk in Patients With Diabetes and Established Cardiovascular Disease on Optimal Medical Therapy: Post Hoc Analysis of ACCELERATE

Diabetes Care. 2020 Feb;43(2):e22-e24. doi: 10.2337/dc19-1117. Epub 2019 Dec 5.

Authors

Nishant P Shah¹, Qiuqing Wang^{2

3}, Katherine E Wolski^{2

3}, Leslie Cho², Ellen McErlean³, Giacomo Ruotolo⁴, Govinda Weerakkody⁴, Jeffrey S Riesmeyer⁴, Stephen J Nicholls⁵, A Michael Lincoff^{2

3}, Steven E Nissen^{2

3}, Venu Menon^{6

3}

Affiliations

¹ Duke University School of Medicine, Durham, NC.
² Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland, OH.
³ C5Research, Cleveland Clinic, Cleveland, OH.
⁴ Eli Lilly and Company, Indianapolis, IN.
⁵ MonashHeart, Monash University, Clayton, Australia.
⁶ Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland, OH menonv@ccf.org.

PMID: 31806654
DOI: 10.2337/dc19-1117

No abstract available

Publication types

Letter
Research Support, Non-U.S. Gov't